Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo

A Multicenter, Randomized, Double-blind, Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Subjects With Non-segmental Vitiligo

This clinical trial is a multicenter, randomized, double-blind, controlled phase II clinical study

Inclusion Criteria:

• The subject understands and voluntarily signs the informed consent form (ICF) and is willing and able to comply with the study protocol.
• The subject is between 18 and 70 years of age (including borderline values) , regardless of gender.

Exclusion Criteria:

• Pregnant or lactating women, or subjects with pregnancy or lactation plans during the study period.
• All hair in the vitiligo area on the face is white.
• Those who are known or suspected to be allergic to the main ingredients and excipients of VC005 or similar drugs.
• Subjects who have previously received depigmentation treatment.
• Subjects who have received experimental drug administration or participated in device clinical trials within the first month or 5 half lives (whichever is longer) prior to randomization.